Basmah Jalil, MD
Rheumatology · Tulsa, OKNPI 1649587635
Payments from drug & device makers
Across 989 payments — averaging $5252.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$4.7M
- Seqirus USA Inc$368K
- AstraZeneca$59K
- Janssen Research & Development, LLC$23K
- Orasure Technologies Inc.$6K
- Biogen$2K
- plus $5K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 483 | $4,730,358 |
| Seqirus USA Inc | 145 | $367,885 |
| AstraZeneca(2 entities) | 10 | $59,462 |
| Janssen Research & Development, LLC | 10 | $23,397 |
| Orasure Technologies Inc. | 4 | $6,467 |
| Biogen | 16 | $2,115 |
| AbbVie | 118 | $1,529 |
| Amgen(2 entities) | 40 | $705 |
| UCB, Inc. | 36 | $703 |
| Lilly USA, LLC | 18 | $327 |
| Johnson & Johnson | 18 | $312 |
| GSK | 12 | $268 |
| Novartis | 18 | $219 |
| Mallinckrodt Hospital Products Inc. | 9 | $174 |
| E.r. Squibb & Sons, L.L.C. | 9 | $130 |
| Pfizer | 10 | $129 |
| Sobi, Inc | 4 | $102 |
| Aurinia Pharma U.S., Inc. | 5 | $81 |
| Actelion Pharmaceuticals US, Inc. | 2 | $56 |
| Boehringer Ingelheim | 3 | $56 |
| Collegium Pharmaceutical, Inc. | 3 | $49 |
| Antares Pharma, Inc. | 3 | $40 |
| Madrigal Pharmaceuticals | 1 | $29 |
| Genentech USA, Inc. | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Mallinckrodt Enterprises LLC | 2 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Radius Health, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $11 |
| Almatica Pharma LLC | 1 | $11 |
How this compares
$5,194,756 in reported general payments places this provider in the 95th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Tulsa
- James McKayTulsa$945K
- Debbie FoleyTulsa$488K
- William SurbeckTulsa$82K
- Ellen ZanetakisTulsa$80K
- Alan MartinTulsa$22K
- Mary Hinojos MamutTulsa$21K
- Manuel CalvinTulsa$19K
- Michael MalloyTulsa$13K
- Priyatha GarlapatiTulsa$8K
- Lindsay CunninghamTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.